ImmunoCellular Therapeutics (NASDAQ:IMUC) posted its quarterly earnings results on Monday. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.06) by $0.02, Stock Ratings News reports.
A number of analysts have recently weighed in on IMUC shares. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $3.31.
Shares of ImmunoCellular Therapeutics (NASDAQ:IMUC) opened at 0.89 on Tuesday. ImmunoCellular Therapeutics has a 52 week low of $0.65 and a 52 week high of $4.00. The stock has a 50-day moving average of $1.02 and a 200-day moving average of $1.18. The company’s market cap is $51.6 million.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
Receive News & Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.